Encouraging Results from Lexicon Candidate - Analyst Blog

A generic image of a person with a calculator and a paper with a chart on it.
Credit: Shutterstock photo

Lexicon Pharmaceuticals, Inc. ( LXRX ) announced encouraging results from a phase II study on its diabetes candidate, LX4211. The candidate, designed to lower blood glucose levels through two insulin-independent mechanisms, is being developed for the treatment of type 1 diabetes.

Results from the study revealed that LX4211 was successful in reducing the total daily mealtime bolus insulin dose by a higher percentage compared to placebo. This was the primary objective of the study. Results further revealed that LX4211 significantly improved glycemic control compared to that of placebo. Moreover, the candidate was well tolerated during the study.

Meanwhile, Lexicon stated in its conference call that it has submitted a request to the FDA regarding an end-of-phase-II meeting for LX4211. Lexicon intends to initiate a phase III study on the candidate for the type 1 diabetes indication by year end. The main objective of the phase III study will be hemoglobin A1c reduction.

We are encouraged by Lexicon's progress with LX4211. The successful development of LX4211 is important for the company. However, at this point, the diabetes market looks extremely crowded with the presence of companies like Novo Nordisk ( NVO ).

Apart from LX4211, Lexicon also has telotristat etiprate and LX1033 in its pipeline. Telotristat etiprate is currently being developed for the treatment of carcinoid syndrome in a phase III study. Meanwhile, LX1033 is in a phase II study to reduce serotonin production without impacting brain serotonin levels.

Lexicon currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks include Amgen Inc. ( AMGN ) and Regeneron Pharmaceuticals, Inc. ( REGN ). Both stocks carry a Zacks Rank #1 (Strong Buy).

AMGEN INC (AMGN): Free Stock Analysis Report

LEXICON PHARMA (LXRX): Free Stock Analysis Report

NOVO-NORDISK AS (NVO): Free Stock Analysis Report

REGENERON PHARM (REGN): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story


Other Topics


Latest Markets Videos


Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at

Learn More